IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
Lu, Jing1; Lu, Jin2,3; Liu, Aijun4; Fu, Weijun1; Du, Juan1; Huang, Xiaojun2,3; Chen, Wenming4; Hou, Jian1
刊名BIOMED RESEARCH INTERNATIONAL
2015
DOI10.1155/2015/856704
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biotechnology & Applied Microbiology ; Medicine, Research & Experimental
研究领域[WOS]Biotechnology & Applied Microbiology ; Research & Experimental Medicine
关键词[WOS]CLINICAL-FEATURES ; SCORING SYSTEM ; ISS ; GUIDELINES ; SURVIVAL ; STRATIFICATION ; DELETION ; CRITERIA
英文摘要

The International Staging System (ISS) is the most important prognostic system for multiple myeloma (MM). It was identified in the era of conventional agents. The outcome of MM has significantly changed by novel agents. Thus the applicability of ISS system in the era of novel agents in Chinese patients needs to be demonstrated. We retrospectively analyzed the clinical outcomes and prognostic significance of ISS system in 1016 patients with newly diagnosed multiple myeloma in Chinese patients between 2008 and 2012, who received bortezomib-or thalidomide-based regimens as first-line therapy. The median overall survival (OS) of patients for ISS stages I/II/III was not reached/55.4 months/41.7 months (p < 0.001), and the median progression-free survival (PFS) was 30/29.5/25 months (p = 0.072), respectively. Statistically significant difference in survival was confirmed among three ISS stages in thalidomide-based group, but not between ISS stages I and II in bortezomib-based group. These findings suggest that ISS system can predict the survival in the era of novel agents in Chinese MM patients, and bortezomib may have the potential to partially overcome adverse effect of risk factors on survival, especially in higher stage of ISS system.

语种英语
WOS记录号WOS:000365925600001
项目编号81172248 ; 81470360 ; 12ZCDZSY17600
资助机构Natural Science Foundation of China ; Tian Jin Municipal Special Foundation for Anticancer
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65843
专题北京大学第二临床医学院
北京大学第二临床医学院_血液科
作者单位1.Second Mil Med Univ, Dept Hematol, Myeloma & Lymphoma Ctr, Changzheng Hosp, Shanghai 200003, Peoples R China
2.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
3.Peking Univ, Inst Hematol, Beijing 100044, Peoples R China
4.Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing 100020, Peoples R China
推荐引用方式
GB/T 7714
Lu, Jing,Lu, Jin,Liu, Aijun,et al. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis[J]. BIOMED RESEARCH INTERNATIONAL,2015.
APA Lu, Jing.,Lu, Jin.,Liu, Aijun.,Fu, Weijun.,Du, Juan.,...&Hou, Jian.(2015).The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.BIOMED RESEARCH INTERNATIONAL.
MLA Lu, Jing,et al."The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis".BIOMED RESEARCH INTERNATIONAL (2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lu, Jing]的文章
[Lu, Jin]的文章
[Liu, Aijun]的文章
百度学术
百度学术中相似的文章
[Lu, Jing]的文章
[Lu, Jin]的文章
[Liu, Aijun]的文章
必应学术
必应学术中相似的文章
[Lu, Jing]的文章
[Lu, Jin]的文章
[Liu, Aijun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。